Triple negative breast cancer-BCL2 in prognosis and prediction. Review

Current Drug Targets

Volumn 15, Issue 12, 2014, Pages 1166-1175

  Bouchalova, Katerina ^a   Kharaishvili, Gvantsa ^a   Bouchal, Jan ^a   Vrbkova, Jana ^a   Megova, Magdalena ^a   Hlobilkova, Alice ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Adjuvant chemotherapy; Anthracycline; BCL2; Neoadjuvant chemotherapy; Predictive factor; Prognostic factor; Triple negative breast cancer

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL) PROPYLAMINO] 3 NITROBENZENESULFONYL] BENZAMIDE; ANTHRACYCLINE; ANTIMYCIN A1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN RECEPTOR; FLUDARABINE; FLUOROURACIL; ISOSORBIDE; KI 67 ANTIGEN; LAPATINIB; METHOTREXATE; NAVITOCLAX; OBATOCLAX; PACLITAXEL; POLYPHENOL; PREDNISONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BCL2 GENE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTO ONCOGENE; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; TRIPLE NEGATIVE BREAST CANCER; FEMALE; GENETICS; METABOLISM; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926307606     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141106151143     Document Type: Article

References (69)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
3. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
4. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 13-17.
5. Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. Ann Oncol 2012; 23: 305-11.
6. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw 2011; 9: 136-222.
7. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812-23.
8. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.
9. Kim K, Chie EK, Han W, et al. Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breastconserving surgery in early breast cancer. Tumori 2011; 97: 280-5.
10. Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099-109.
11. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-41.
12. Online Mendelian Inheritance in Man. An Online Catalog of Genes and Genetic Disorders. http://www.omim.org/(Accessed March 13, 2014).
13. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994; 54: 3714-7.
14. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979-90.
15. Zeitlin BD, Nor JE. Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. Curr Top Microbiol Immunol 2011; 348: 115-37.
16. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145: 515-25.
17. Krajewski S, Krajewska M, Ehrmann J, et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-14.
18. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997; 3: 199-208.
19. Papajik T, Jedlickova K, Kriegova E, et al. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma 2001; 48: 501-505.
20. Salles G, de JD, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-8.
21. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-32.
22. Skommer J, Wlodkowic D, Deptala A. Larger than life: Mitochondria and the Bcl-2 family. Leuk Res 2007; 31: 277-86.
23. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
24. Takeda K, Naguro I, Nishitoh H, Matsuzawa A, Ichijo H. Apoptosis signaling kinases: from stress response to health outcomes. Antioxid Redox Signal 2011; 15: 719-61.
25. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-28.
26. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-9.
27. Leung LK, Wang TT. Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. Br J Cancer 1999; 81: 387-92.
28. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 2000; 53: 15-8.
29. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph nodenegative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
30. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
31. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103 : 668-75.
32. Kim HS, Moon HG, Han W, et al. COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Res Treat 2012; 132: 51-9.
33. Ganten TM, Sykora J, Koschny R, et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009; 87: 995-1007.
34. Dedes KJ, Natrajan R, Lambros MB, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 2011; 47: 138-50.
35. Berardo MD, Elledge RM, de MC, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998; 82: 1296-302.
36. Charpin C, Garcia S, Bonnier P, et al. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol 1998; 16: 2025-31.
37. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-75.
38. Neri A, Marrelli D, Roviello F, et al. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat 2006; 99: 77-83.
39. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008; 8: 153.
40. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
41. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999; 6: 61-8.
42. Sjostrom J, Blomqvist C, von BK, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002; 8: 811-6.
43. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999; 6: 29-40.
44. Chang JC, Hilsenbeck SG. Prognostic and predictive markers. In Harris JR, et al. Diseases of the Breast. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams&Wilkins 2010, 443-57.
45. Kallel-Bayoudh I, Hassen HB, Khabir A, et al. Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol 2011; 28: (Suppl 1, S55-S61).
46. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-9.
47. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-7.
48. Tsutsui S, Yasuda K, Suzuki K, et al. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer 2006; 6: 187.
49. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable nodepositive breast cancer. Clin Cancer Res 1995; 1: 189-98.
50. Ali HR, Dawson SJ, Blows FM, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012; 226: 97-107.
51. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-6.
52. Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol 2009; 14: 112-19.
53. Pusztai L, Krishnamurti S, Perez CJ, et al. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 2004; 22: 248-56.
54. Dickinson PD, Abdel-Fatah TMA, Green AR, et al. Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy. J Clin Oncol 2011; 29: (suppl; abstr 589).
55. Abdel-Fatah TMA, Dickinson PD, Moseley P, et al. Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. J Clin Oncol 2011; 29: (suppl; abstr 1024).
56. Abdel-Fatah TM, Perry C, Dickinson P, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol 2013; 24: 2801-7.
57. Bouchalova K, Svoboda M, Kharaishvili G, et al. BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol 2012; 30: (suppl; abstr 1087).
58. Bouchalova K, Cizkova M, Trojanec R, et al. BCL2 is a predictive marker of adjuvant CMF regimen in triple negative breast cancer (TNBC) patients. Breast Cancer Research 2011; 13:(Suppl 2; P8; doi: 10.1186/bcr3029).
59. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-53.
60. Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DM. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000; 85: 829-35.
61. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 2010; 16: 2138-46.
62. Paoluzzi L, O'Connor OA. Targeting survival pathways in lymphoma. Adv Exp Med Biol 2010; 687: 79-96.
63. Oakes SR, Vaillant F, Lim E, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 2012; 109: 2766-71.
64. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7: R940-R952.
65. Moulder SL, Symmans WF, Booser DJ, et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008; 14: 7909-16.
66. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-64.
67. Lee KH, Im SA, Oh DY, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007; 7: 63.
68. Bottini A, Berruti A, Bersiqa A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001; 85: 1106-12.
69. Choi JE, Kang SH, Lee SJ, Bae YK. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. Tumour Biol. 2014 Sep 2. [Epub ahead of print] PMID: 25179840.